American Association of Oral and Maxillofacial Surgeons Oral and maxillofacial surgeons:
The experts in face, mouth and jaw surgeryยฎ

Nonprescription opioid antagonist nasal spray approved

The FDA on July 28 approved RiVive, 3 mg naloxone hydrochloride nasal spray for over-the-counter, nonprescription use for the emergency treatment of known or suspected opioid overdose. With drug overdose persisting as a major public health issue in the United States, approval of this nonprescription product helps increase consumer access to naloxone. As part of the FDAโ€™s Overdose Prevention Framework, the agency continues to take actionable steps to increase availability and expand access to overdose reversal products.

More information is available at FDA.gov.

QUICK
LINKS